Small molecules targeting c-Myc oncogene: Promising anti-cancer therapeutics

International Journal of Biological Sciences

Volumn 10, Issue 10, 2014, Pages 1084-1096

  Chen, Bing Jia ^a   Wu, Yan Ling ^a,b   Tanaka, Yoshimasa ^c   Zhang, Wen ^a  

^a ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^b ZHEJIANG PROVINCIAL CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

c Myc; G quadruplex; Small molecule; Targeted therapy; Tumor

Indexed keywords

ALKALOID; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOXAZINE DERIVATIVE; GUANINE QUADRUPLEX; HOECHST 32258; INDOLE DERIVATIVE; LIGAND; MYC PROTEIN; MYC PROTEIN, HUMAN; PERYLENE; QUARFLOXIN; QUINDOLINE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

APOPTOSIS; CELL TRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; DIMERIZATION; DRUG DEVELOPMENT; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE STRUCTURE; GENETICS; HUMAN; METABOLISM; NEOPLASMS; PHYSIOLOGY; PROCEDURES; RIBOSOME;

ALKALOIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; BENZOXAZINES; CELL TRANSFORMATION, NEOPLASTIC; DIMERIZATION; DRUG DISCOVERY; G-QUADRUPLEXES; GENE COMPONENTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; LIGANDS; MOLECULAR STRUCTURE; NEOPLASMS; PERYLENE; PROTO-ONCOGENE PROTEINS C-MYC; QUINOLINES; QUINOLONES; RIBOSOMES;

EID: 84907879938     PISSN: 14492288     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijbs.10190     Document Type: Article

References (139)

1. Dang C V. MYC on the Path to Cancer. Cell. 2012; 149(1): 22-35.
2. Fernandez PC, Frank S R, Wang L, et al. Genomic targets of the human c-Myc protein. Genes & development. 2003; 17(9): 1115-1129.
3. Li Z, Van Calcar S, Qu C, et al. A global transcriptional regulatory role for c-Myc in Burkitt’s lymphoma cell. PNAS. 2003; 100(14): 8164-8169.
4. Lin CY, Lovén J, Rahl PB, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012; 151(1): 56-67.
5. Zhang X, Zhao X, Fiskus W, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas. Cancer cell. 2012; 22(4): 506-523.
6. Berg T. Small-molecule modulators of c-Myc/Max and Max/Max interaction. Curr Top Microbio Immunol. 2011; 348: 139-149.
7. Lin CP, Liu CR, Lee CN, et al. Targeting c-Myc as a novel approach for hepa-tocellular carcinoma. World J Hepatol. 2010; 2(1): 16-20.
8. Zhang W, Kater AP, Widhopf GF, et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. PNAS. 2010; 107(44): 18956-18960.
9. Watt R, Nishikura K, Sorrentino J, et al. The structure and nucleotide sequence of the 5'end of the human c-myc oncogene. PNAS. 1983; 80(20): 6307-6311.
10. Islam MA, Thomas SD, Murty VV, et al. c-Myc quadruplex-forming sequence Pu-27 induces extensive damage in both telomeric and non-telomeric regions of DNA. J Biol Chem. 2014: jbc.M113.505073.
11. Simonsson T, Pribylova M, Vorlickova M. A Nuclease Hypersensitive Element in the human c-myc promoter adopts several distinct i-tetraplex structures. Biochem Biophys Res Commun. 2000; 278(1): 158-166.
12. Seenisamy J, Bashyam S, Gokhale V, et al. Design and synthesis of an ex-panded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J Am Chem Soc. 2005; 127(9): 2944-2959.
13. Cashman DJ, Buscaglia R, Freyer MW, et al. Molecular modeling and bio-physical analysis of the c-MYC NHE-III1 silencer element. J Mol Model. 2008; 14(2): 93-101.
14. Soucek L, Evan G. Myc-Is this the oncogene from Hell? Cancer Cell. 2002; 1(5): 406-408.
15. Vafa O, Wade M, Kern S, et al.c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for onco-gene-induced genetic instability. Mol Cell. 2002; 9(5): 1031-1044.
16. Zhang Q, Spears E, Boone DN, et al. Domain-specific c-Myc ubiquitylation controls c-Myc transcriptional and apoptotic activity. PNAS. 2013; 110(3): 978-983.
17. Song G, Li Y, Zhang Z, et al.c-myc but not Hif-1α-dependent downregulation of VEGF influences the proliferation and differentiation of HL-60 cells induced by ATRA. Oncol Rep. 2013; 29(6): 2378-2384.
18. Alblihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010; 107: 163-224.
19. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011; 146(6): 904-917.
20. Sakamuro D, Prendergast GC. New Myc-interacting proteins: a second Myc network emerges. Oncogene. 1999; 18(19): 2942-2954.
21. Ponzielli R, Katz S, Barsyte-Lovejoy D, et al. Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer. 2005; 41(16): 2485-2501.
22. Pelengaris S, Khan M. The many faces of c-MYC. Arch Biochem Biophys. 2003; 416(2): 129-136.
23. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151(1): 68-79.
24. Cartwright P, McLean C, Sheppard A, et al. LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. Develop-ment. 2005; 132(5): 885-896.
25. Baudino TA, McKay C, Pendeville-Samain H, et al.c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002; 16(19): 2530-2543.
26. Cavalheiro GR, Matos-Rodrigues GE, Gomes AL, et al.c-myc regulates cell proliferation during Lens development. PloS one. 2014; 9(2): e87182.
27. Krysan K, Kusko R, Grogan T, et al. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC. Mol Cancer Res. 2014; molcanres-0377.
28. Amati B. Integrating Myc and TGF-β signalling in cell-cycle control. Nat Cell Biol. 2001; 3(5): E112-E113.
29. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003; 17(9): 1115-1129.
30. Bouchard C, Dittrich O, Kiermaier A, et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruit-ment and histone acetylation at the cyclin D2 promoter. Genes Dev. 2001; 15(16): 2042-2047.
31. Menssen A, Hermeking H. Characterization of the c-MYC-regulated tran-scriptome by SAGE: identification and analysis of c-MYC target genes. PNSA. 2002; 99(9): 6274-6279.
32. Hermeking H, Rago C, Schuhmacher M, et al. Identification of CDK4 as a target of c-MYC. PNAS. 2000; 97(5): 2229-34.
33. Gomez-Roman N, Grandori C, Eisenman R N, et al. Direct activation of RNA polymerase III transcription by c-Myc. Nature. 2003; 421(6920): 290-294.
34. Steiner P, Philipp A, Lukas J, et al. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. 1995; 14(19): 4814-4836.
35. Bouchard C, Thieke K, Maier A, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999; 18(19): 5321-5333.
36. Staller P, Peukert K, Kiermaier A, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001; 3(4): 392-399.
37. Wu S, Cetinkaya C, Munoz-Alonso M J, et al. Myc represses differentia-tion-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene. 2003; 22(3): 351-360.
38. Seoane J, Pouponnot C, Staller P, et al. TGF-β influences Myc, Miz-1 and Smad to control the CDK inhibitor p15INK4b. Nat Cell Biol. 2001; 3(4): 400-408.
39. Seoane J, Le H V, Massagué J. Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 2002; 419(6908): 729-734.
40. Coller HA, Grandori C, Tamayo P, et al. Expression analysis with oligonucle-otide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. PNAS.2000; 97(7): 3260-3265.
41. Chapman N, Webster G, Gillespie P, et al. A novel form of the RelA nuclear factor κB subunit is induced by and forms a complex with the proto-oncogene c-Myc. Biochem J. 2002; 366: 459-469.
42. Gordan J D, Bertout J A, Hu C J, et al. HIF-2α promotes hypoxic cell prolifera-tion by enhancing c-Myc transcriptional activity. Cancer cell. 2007; 11(4): 335-347.
43. Van Riggelen J, Yetil A, Felsher DW. MYC as a regulator of ribosome biogen-esis and protein synthesis. Nat Rev Cancer. 2010; 10(4): 301-309.
44. Mateyak MK, Obaya AJ, Adachi S, et al. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Dif-fer. 1997; 8(10): 1039-1048.
45. Orian A, van Steensel B, Delrow J, et al. Genomic binding by the Drosophila Myc, Max, Mad/Mnt transcription factor network. Genes Dev. 2003; 17(9): 1101-1014.
46. Mao DY, Watson JD, Yan PS, et al. Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol. 2003; 13(10): 882-886.
47. Grandori C, Gomez-Roman N, Felton-Edkins ZA, et al.c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA poly-merase I. Nature Cell Biol. 2005; 7(3): 311-318.
48. Li Z, Hann SR. Nucleophosmin is essential for c-Myc nucleolar localization and c-Myc-mediated rDNA transcription. Oncogene. 2013; 32(15): 1988-1994.
49. Schlosser I, Hölzel M, Mürnseer M, et al. A role for c-Myc in the regulation of ribosomal RNA processing. Nucleic Acids Res. 2003; 31(21): 6148-6156.
50. Grewal SS, Li L, Orian A, et al. Myc-dependent regulation of ribosomal RNA synthesis during Drosophila development. Nat Cell Biol. 2005; 7(3): 295-302.
51. Pourdehnad M, Truitt M L, Siddiqi I N, et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. PNAS. 2013; 110(29): 11988-11993.
52. Nie Z, Hu G, Wei G, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012; 151(1): 68-79.
53. Betschinger J, Mechtler K, Knoblich JA. Asymmetric segregation of the tumor suppressor brat regulates self-renewal in Drosophila neural stem cells. Cell. 2006; 124(6): 1241-1253.
54. Schwamborn JC, Berezikov E, Knoblich JA. The TRIM-NHL protein TRIM32 activates microRNAs and prevents self-renewal in mouse neural progenitors. Cell. 2009; 136(5): 913-925.
55. Wumesh KC, Satpathy AT, Rapaport AS, et al. L-Myc expression by dendritic cells is required for optimal T-cell priming. Nature. 2014.
56. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; (8): 976-990.
57. Larsson LG. Henriksson MA. The Yin and Yang functions of the Myc onco-protein in cancer development and as targets for therapy. Exp Cell Res. 2010; 316(8): 1429-1437.
58. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 2009; 9 (7): 501-507.
59. Inoue S, Hao Z, Elia AJ, et al. Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. Genes Dev. 2013; 27(10): 1101-1114.
60. Herkert B, Eilers M. Transcriptional repression the dark side of Myc. Genes Cancer. 2010; 1(6): 580-586.
61. Eischen CM, Woo D, Roussel MF, et al. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001; 21(15): 5063-5070.
62. Martinou JC, Green DR. Breaking the mitochondrial barrier. Nat Rev Mol Cell Biol. 2001; 2(1): 63-67.
63. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008; 27(50): 6462-6472.
64. O'Donnell KA, Wentzel EA, Zeller KI, et al.c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 2005; 435(7043): 839-843.
65. Ma L, Young J, Prabhala H, et al.miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010; 12(3): 247-256.
66. Chang TC, Yu D, Lee Y S, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2007; 40(1): 43-50.
67. Gao P, Tchernyshyov I, Chang TC, et al.c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009; 458(7239): 762-765.
68. Dews M, Homayouni A, Yu D, et al. Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006; 38(9): 1060-1065.
69. Bui TV, Mendell JT. Myc Maestro of MicroRNAs. Genes & cancer. 2010; 1(6): 568-575.
70. Wang X, Zhao X, Gao P, et al. c-Myc modulates microRNA processing via the transcriptional regulation of Drosha. Sci Rep. 2013; 3: 1-7.
71. Davis BN, Hilyard AC, Lagna G, et al. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008; 454(7200): 56-61.
72. Davis BN, Hilyard AC, Nguyen PH, et al. Smad proteins bind a conserved RNA sequence to promote microRNA maturation by Drosha. Mol Cell, 2010; 39(3): 373-384.
73. Suzuki HI, Yamagata K, Sugimoto K, et al. Modulation of microRNA pro-cessing by p53. Nature. 2009; 460(7254): 529-533.
74. Zhang X, Wan G, Berger FG, et al. The ATM kinase induces microRNA bio-genesis in the DNA damage response. Mol Cell. 2011; 41(4): 371-383.
75. Mao G, Lee S, Ortega J, et al. Modulation of microRNA processing by mis-match repair protein MutLα. Cell Res. 2012; 22(6): 973-985.
76. Kawai S, Amano A. BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex. J Cell Biol. 2012; 197(2): 201-208.
77. Neil M, Keith IE. Targeting a c-MYC G-quadruplex DNA with a fragment library. Chem Commun. 2014; 50(14): 1704-1707.
78. Halder K, Mathur V, Chugh D, et al. Quadruplex-duplex competition in the nuclease hypersensitive element of human c-myc promoter: C to T mutation in C-rich strand enhances duplex association. Biochem Biophys Res Commun. 2005; 327: 49-56.
79. Li W, Miyoshi D, Nakano S, et al. Structural competition involving G-Quadruplex DNA and its complement. Biochemistry. 2003; 42: 11736-11744.
80. Risitano A, Fox KR. Stability of intramolecular DNA quadruplexes: compari-son with DNA duplexes. Biochemistry. 2003; 42(21): 6507-6513.
81. Franceschin M. G-Quadruplex DNA structures and organic chemistry: more than one connection. Eur J Org Chem. 2009; 2009(14): 2225-2238.
82. Steele NL, Plumb J A, Vidal L, et al. A phase I pharmacokinetic and pharma-codynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res. 2008; 14(3): 804-810.
83. Brooks TA, Hurley LH. Targeting MYC expression through G-quadruplexes. Genes & cancer. 2010; 1(6): 641-649.
84. Kerwin SM, Chen G, Kern JT, et al. Perylene diimide G-Quadruplex DNA binding selectivity is mediated by ligand aggregation bioorg. Med Chem Lett. 2002; 12(3): 447-450.
85. Li Q, Xiang JF, Zhang H, et al. Searching drug-like anti-cancer compound (s) based on G-quadruplex ligands. Curr Pharm Des. 2012; 18(14): 1973-1983.
86. Pivetta C, Lucatello L, Krapcho AP, et al. Perylene side chains modulate G-quadruplex conformation in biologically relevant DNA sequences. Bioorg Med Chem. 2008; 16(20): 9331-9339.
87. Sun D, Guo K, Rusche JJ, et al. Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res. 2005; 33(18): 6070-6080.
88. Kato GJ, Barrett J, Villa-Garcia M, et al. An amino-terminal c-myc domain required for neoplastic transformation activates transcription. Mol Cell Biol. 1990; 10(11): 5914-5920.
89. Seenisamy J, Rezler EM, Powell TJ, et al. The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4. J Am Chem Soc. 2004; 126(28): 8702-8709.
90. González V, Hurley L H. The c-MYC NHE III1: function and regulation. Annu Rev Pharmacool Toxicol. 2010; 50: 111-129.
91. Andrew EJ, Merchan S, Lawless C, et al. Pentose phosphate pathway function affects tolerance to the G-Quadruplex binder TMPyP4. PloS one. 2013; 8(6): e66242.
92. Verdun RE, Karlseder J. Replication and protection of telomeres. Nature. 2007; 447(7147): 924-931.
93. Ou TM, Lu YJ, Zhang C, et al. Stabilization of G-quadruplex DNA and down-regulation of oncogene c-myc by quindoline derivatives. J Med Chem. 2007; 50(7): 1465-1474.
94. Ou TM, Lin J, Lu YJ, et al. Inhibition of cell proliferation by quindoline deriv-ative (SYUIQ-05) through its preferential interaction with c-myc promoter G-quadruplex. J Med Chem. 2011; 54(16): 5671-5679.
95. Efferth T, Fu Y, Zu Y, et al. Molecular target-guided tumor therapy with natural products derived from traditional Chinese medicine. Curr Med Chem. 2007; 14(19): 2024-2032.
96. Lee HM, Chan DSH, Yang F, et al. Identification of natural product Fonsecin B as a stabilizing ligand of c-myc G-quadruplex DNA by high-throughput vir-tual screening. Chem. Commun. 2010; 46(26): 4680-4682.
97. Shin-ya K, Wierzba K, Matsuo K, et al. Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. J Am Chem Soc. 2001; 123(6): 1262-1263.
98. Liu Y, Zheng B, Xu X, et al. Probing the binding affinity of small-molecule natural products to the G-quadruplex in C-myc oncogene by electrospray ionization mass spectrometry. Rapid Comm Mass Spectrom. 2010; 24(20): 3072-3075.
99. Maiti M, Kumar GS. Protoberberine alkaloids: physicochemical and nucleic acid binding properties. Top Heterocycle Chem. 2007; 10: 155-209.
100. Ji X, Sun H, Zhou H, et al. The interaction of telomeric DNA and c-Myc22 G-quadruplex with 11 natural alkaloids. Nucleic Acid Therapeutics. 2012; 22(2): 127-136
101. Zhang W., Ou TM, Lu YJ, et al. 9-Substituted berberine derivatives as G-quadruplex stabilizing ligands in telomeric DNA. Bioorg Med Chem. 2007; 15(16): 5493-501.
102. Ma Y, Ou TM, Hou JQ, et al. 9-N-Substituted berberine derivatives: stabiliza-tion of G-quadruplex DNA and down-regulation of oncogene c-myc. Bioorg Med Chem. 2008; 16(16): 7582-7591.
103. Vy Thi Le T, Han S, Chae J, et al. G-Quadruplex binding ligands: from natu-rally occurring to rationally designed molecules. Curr Pharm Des. 2012; 18(14): 1948-1972.
104. Ou T, Lu Y, Tan J, et al. G-Quadruplexes: targets in anticancer drug design. ChemMedChem. 2008; 3(5): 690-713.
105. Monchaud D, Teulade-Fichou M P. A hitchhiker’s guide to G-quadruplex ligands. Org Biomol Chem. 2008; 6(4): 627-636.
106. Ho YP, Au-Yeung SCF, To KKW. Platinum-based anticancer agents: innova-tive design strategies and biological perspectives. Med Res Rev. 2003; 23(5): 633-655.
107. Kostova I. Platinum complexes as anticancer agents. Recent Pat Antican Drug Discov. 2006; 1(1): 1-22.
108. Georgiades SN, Abd Karim NH, Suntharalingam K, et al. Interaction of metal complexes with G-quadruplex DNA. Angew Chem Int Ed. 2010; 49(24): 4020-4034.
109. Zhang J, Zhang F, Li H, et al. Recent progress and future potential for metal complexes as anticancer drugs targeting G-quadruplex DNA. Curr Med Chem. 2012; 19(18): 2957-2975.
110. Wang J, Lu K, Xuan S, et al. Pt (II)-Dip complex stabilizes parallel c-myc G-Quadruplexes. Chem Commun. 2013; 49: 4758-4760.
111. Wu P, Ma DL, Leung CH, Yan SC, et al. Stabilization of G-Quadruplex DNA with Platinum(II) schiff base complexes: luminescent probe and down-regulation of c-myc oncogene expression. Chem Eur J. 2009; 15(47): 13008-13021.
112. Maita S, Chaudhury NK, Chowdhury S. Hoechst 33258 binds to G-quadruplex in the promoter region of human c-myc. Biochem Biophys Res Commun. 2003; 310(2): 505-512.
113. Dash J, Shirude PS, Hsu STD, et al. Diarylethynyl amides that recognize the parallel conformation of genomic promoter DNA G-Quadruplexes. J Am Chem Soc. 2008; 130(47): 15950-15956.
114. Chen Q, Kuntz ID, Shafer RH. Spectroscopic recognition of guanine dimeric hairpinquadruplexes by a carbocyanine dye. PNAS. 1996; 93(7): 2635-2639.
115. Cheng JY, Lin SH, Chang TC. Vibrational investigation of DODC cation for recognition of guanine dimeric hairpin quadruplex studied by satellite holes. J Phys Chem B. 1998; 102(28): 5542-5546.
116. White EW, Tanious F, Ismail MA, et al. Structure-specific recognition of quadruplex DNA by organic cations: Influence of shape, substituents and charge. Biophys Chem. 2007; 126(1): 140-153.
117. Ma DL, Chan DSH, Fu WC, et al. Discovery of a natural product-like c-myc G-quadruplex DNA groove-binder by molecular docking. PloS one. 2012; 7(8): e43278.
118. Lemarteleur T, Gomez D, Paterski R, et al. Stabilization of the c-myc gene promoter quadruplex by specific ligands’ inhibitors of telomerase. Biochemi-cal and Biophysical Research Communications. 2004; 323(3): 802-808.
119. Zhang S-L, Wu Y-L, Zhang W. G-Quadruplex structures and their interaction diversity with ligands. ChemMedChem. 2014; 9: 899-911.
120. Gabelica V, Baker ES, Teulade-Fichou MP, et al. Stabilization and structure of telomeric and c-myc region intramolecular G-quadruplexes: the role of central cations and small planar ligands. J Am Chem Soc. 2007; 129(4): 895-904.
121. Lüscher B, Vervoorts J. Regulation of gene transcription by the oncoprotein MYC. Gene. 2012; 494(2): 145-160.
122. Amati B, Brooks M W, Levy N, et al. Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell. 1993; 72(2): 233-245.
123. Berg T. Inhibition of transcription factors with small organic molecules. Curr Opin Chem Biol. 2008; 12(4): 464-471.
124. Wang H, Hammoudeh DI, Follis AV, et al. Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther. 2007; 6(9): 2399-2408.
125. Kiessling A, Sperl B, Hollis A, et al. Selective inhibition of c-Myc/Max dimer-ization and DNA binding by small molecules. Chem Biol. 2006; 13(7): 745-751.
126. Yap JL, Chauhan J, Jung KY, et al. Small-molecule inhibitors of dimeric tran-scription factors: Antagonism of protein-protein and protein-DNA interac-tions. Med Chem Comm. 2012; 3(5): 541-551.
127. Berg T, Cohen SB, Desharnais J, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibro-blasts. PNAS. 2002; 99(6): 3830-3835.
128. Lu X, Vogt PK, Boger DL, et al. Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization. Oncol Rep. 2008; 19(3): 825-830.
129. Yin X, Giap C, Lazo J S, et al. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 2003; 22(40): 6151-6159.
130. Xu Y, Shi J, Yamamoto N, et al. A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem. 2006; 14(8): 2660-2673.
131. Kiessling A, Wiesinger R, Sperl B, et al. Selective inhibition of c-Myc/Max dimerization by a pyrazolo [1,5-a] pyrimidine. ChemMedChem. 2007; 2(5): 627-630.
132. Hammoudeh DI, Follis AV, Prochownik EV, et al. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc. 2009; 131(21): 7390-7401.
133. Shi J, Stover JS, Whitby LR, et al. Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation. Bioorg Med Chem Lett. 2009; 19(21): 6038-6041.
134. Follis AV, Hammoudeh DI, Daab AT, et al. Small-molecule perturbation of competing interactions between c-Myc and Max. Bioorg Med Chem Lett. 2009; 19(3): 807-810.
135. Guo J, Parise RA, Joseph E, et al. Efficacy, pharmacokinetics, tisssue distribu-tion, and metabolism of the Myc-Max disruptor, 10058-F4 [Z, E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemoth Pharm. 2009; 63(4): 615-625.
136. Mo H, Henriksson M. Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. PNAS. 2006; 103(16): 6344-6349.
137. Mustata G, Follis AV, Hammoudeh DI, et al. Discovery of novel myc-max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem. 2009; 52(5): 1247-1250.
138. Wang H, Chauhan J, Hu A, et al. Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5. Oncotarget. 2013; 4(6): 936-947.
139. Follis AV, Hammoudeh DI, Wang H, et al. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol. 2008; 15(11): 1149-1155.